September 2, 2016
L.O.M. Medical International Inc. and L.O.M. Laboratories Inc. (together “LOMMI”) have completed three significant steps toward bringing our 3 ml Retractable Safety Syringe into production and onto the market:
First: Symbient Product Development has completed production quality molds and they will soon produce a designated quantity of syringes required for US FDA and European CE certification.
Second: LOMMI has contracted CE Medical Experts to complete the FDA and CE certifications. CE Medical Experts have confirmed that the laboratories of Smithers Viscenes Ltd. (“Smithers”) in the United Kingdom will conduct the required laboratory process required for both certifications. Further, Smithers would be able to start carrying out the testing for both FDA and CE, thus reducing the time for both certifications between 3 – 4 months.
Third: LOMMI has signed an Original Equipment Manufacturer agreement with Shanghai Kindly Development Group Ltd (“KDL”). KDL is a major syringe manufacturer for a number of the largest syringe companies in the world. KDL will first build up to 20,000 3 mL syringes that LOMMI will use for pre-marketing purposes of our syringe Intellectual Property to our interested distributors.
The efforts of the Board of Directors and the Advisory Board to place shares at $7.00 and the Bridge Loan have met with limited success to date. Therefore, the Board has decided that a private placement is necessary to maintain the momentum gained by the recent developments and improve LOMMI’s financial position. Additionally, part of the proceeds of a private placement would be used to repay $900,000 of debt, which is accruing interest, thereby reducing available funds to pay for capturing the advances that have been achieved.
To this end, the Board has decided to offer an opportunity to participate in a CAD$3 million private placement (the “Private Placement”) in which current shareholders of L.O.M. Laboratories Inc. (“L.O.M. Canada”) and L.O.M. Medical International Inc. (“L.O.M. US”) will have the first right to participate in the issue of up to 1,500,000 Class B Common shares (each an “L.O.M. Canada B Share”) in L.O.M. Canada at a price at $2.00 per L.O.M. Canada B Share. The discounted price reflects in part a reward to those who have waited and supported L.O.M. Canada and L.O.M. US in the long past, while providing encouragement and benefit to shareholders to continue supporting L.O.M. Canada to achieve its objectives promptly.
Below you will find the term sheet for the Private Placement, which explains the procedure for the conduct of the offering, along with the Subscription Agreement documentation for participation in the Private Placement.
On Behalf of the Board of Directors
President and CEO